RecruitingNot ApplicableNCT06966674

No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track

Assessment of No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track


Sponsor

Kafrelsheikh University

Enrollment

60 participants

Start Date

May 12, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to assess the no-reflow in patients with STEMI after intracoronary glycoprotein IIb/IIIa inhibitors after opening of track in thrombus.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Age ≥ 18 years old.
  • Both sexes.
  • Patients with STEMI. ST-segment elevated myocardial infarction is defined as typical chest pain \>30 minutes with ST-segment elevation of \>1 mm in at least 2 consecutive leads on the electrocardiogram or new-onset left bundle brunch block.

Exclusion Criteria7

  • Treatment with thrombolytic drugs in the previous 24 hours.
  • Known malignancy.
  • Thrombocytopenia.
  • End-stage liver disease.
  • Cardiogenic shock.
  • Renal failure with glomerular filtration\<30 ml/min.
  • Contraindication for the use of tirofiban.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIntracoronary tirofiban

Patients will receive intracoronary tirofiban (Aggrastat®) (25 mg/kg).

DRUGSaline 0.9%

Patients will receive intracoronary saline 0.9% solution as a control group.


Locations(1)

Kafrelsheikh University

Kafr ash Shaykh, Kafrelsheikh, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06966674


Related Trials